0000897069-14-000156.txt : 20140219 0000897069-14-000156.hdr.sgml : 20140219 20140219145059 ACCESSION NUMBER: 0000897069-14-000156 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140219 DATE AS OF CHANGE: 20140219 EFFECTIVENESS DATE: 20140219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Reven Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556231 IRS NUMBER: 000000000 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-212162 FILM NUMBER: 14625270 BUSINESS ADDRESS: STREET 1: 4411 BEE RIDGE ROAD STREET 2: SUITE 285 CITY: SARASOTA STATE: FL ZIP: 34233 BUSINESS PHONE: 941-320-9271 MAIL ADDRESS: STREET 1: 4411 BEE RIDGE ROAD STREET 2: SUITE 285 CITY: SARASOTA STATE: FL ZIP: 34233 D 1 primary_doc.xml X0707 D LIVE 0001556231 Reven Pharmaceuticals, Inc. 4411 BEE RIDGE ROAD SUITE 285 SARASOTA FL FLORIDA 34233 941-320-9271 FLORIDA Advanced Diagnostics International of Florida, Inc. Noventis, Inc. None Corporation true Peter B. Lange 4411 Bee Ridge Road Suite 285 Sarasota FL FLORIDA 34233 Executive Officer Director Brian Denomme 4411 Bee Ridge Road Suite 285 Sarasota FL FLORIDA 34233 Executive Officer Director Michael Handley 4411 Bee Ridge Road Suite 285 Sarasota FL FLORIDA 34233 Executive Officer Pharmaceuticals Decline to Disclose 06b false true false true false 50000 Futures Investment Company 42402 None None 5914 North 300 West Fremont IN INDIANA 46737 IN INDIANA true 7000000 0 7000000 false 0 0 0 The Selling Agent will be compensated solely in Shares; 3% of first $620,000 of Shares sold and 2% for the balance of Shares sold at a value of $0.10 per Share. 850000 true This estimate reflects the maximum amount to be used for management and personnel costs if Total Offering Amount raised. false Reven Pharmaceuticals, Inc. Peter B. Lange Peter B. Lange President 2014-02-19